Team 11

Alpha Invo: Chameleon Diagnostic Gauze

Team Members: Alexandra Davis, Breanna Isbell, Matthew Peters - SBHSE

Team Mentors: Dr. Brent Vernon - SBHSE
Dr. Olivia Burnsed - SBHSE
Dr. Mark Slayton - Ohio University Heritage College of Osteopathic Medicine

YouTube Link: View the video link below before joining the zoom meeting

Zoom Link: https://asu.zoom.us/j/91587415825

Abstract

Approximately $13.1M of Medicare is spent annually on surgical wound infections; additionally, $6.9M is spent on diabetic foot ulcers for a combined total of $20M USD. Majority

of the market compounds breakdown between acute wounds, chronic wounds, and surgical wounds. The global wound dressing market was estimated to be $3080M USD as of 2018 with a compound annual growth rate (CAGR) of 5.6% annually until 2025. Surgical site infection (SSI) is one of the most common hospital acquired infections (HAI) and costs the healthcare system $3.5 to $10B annually. The Center for Infectious Disease Research and Policy (CIDRAP) reported that there were 14.3M cases of bacterial infection in the United States and of those, 1.6M were antibiotic resistant infections. Antibiotic resistant infections have doubled in the past decade, making timely diagnosis imperative, especially with our two target markets. A wound dressing that counters as a swift, passive detection device would be beneficial for our two target market segments: diabetic ulcers and surgical site infections. The novel device in development is a diagnostic gauze to decrease detection time for pathogenic Staphylococcus aureus (S. aureus) infections through the use of toxin-sensitive liposomes. Alpha Invo’s Chameleon Diagnostic Gauze, originally devised in the summer of 2019, would be a game changer for the wound care industry in both reducing adverse effects of wound infections and reducing healthcare costs. Utilizing a cascading system of indicative reactions, immobilized enzymes, and visual indicators, the dressing will act as both a passive and swift detection system for pathogenic S. aureus bacteria. Through multiple segmented prototype tests, isolated specification analysis, and various protocol iterations and adjustments, Alpha Invo has successfully researched and set our protocols for the development of the device. The team has tested as far as possible with the capacity of Capstone and under the current circumstances.

Video: